Market Cap : 199.97 M | Enterprise Value : 133.28 M | PE Ratio : At Loss | PB Ratio : 3.00 |
---|
NAS:VTGN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:VTGN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 5-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
As of today (2022-06-28), VistaGen Therapeutics's 5-Day RSI is 37.02.
The industry rank for VistaGen Therapeutics's 5-Day RSI or its related term are showing as below:
VTGN's 5-Day RSI is ranked better thanFor the Biotechnology subindustry, VistaGen Therapeutics's 5-Day RSI, along with its competitors' market caps and 5-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, VistaGen Therapeutics's 5-Day RSI distribution charts can be found below:
* The bar in red indicates where VistaGen Therapeutics's 5-Day RSI falls into.
The formula for calculating RSI is:
RSI | = | 100 | – | [ 100 | / | ( 1 + Average Gain | / | Average Loss )] |
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 5-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Thank you for viewing the detailed overview of VistaGen Therapeutics's 5-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.
Saxe Jon S | director | FIRST HORIZON PHARMACEUTICAL CORP 660 HEMBREE PKWY STE 106 ROSWELL GA 30076 |
Dotson Jerrold Duane | officer: VP, CFO AND SECRETARY | 5 CENTERPOINTE DRIVE SUITE 400 LAKE OSWEGO OR 97035 |
Singh Shawn | director, officer: CHIEF EXECUTIVE OFFICER | C/O VISTAGEN THERAPEUTICS, INC. 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080 |
Snodgrass H. Ralph | director, officer: PRES./CHIEF SCIENTIFIC OFFICER | 384 OYSTER POINT BLVD. SUITE 8 SOUTH SAN FRANCISCO CA 94080 |
Smith Mark Alan | officer: CHIEF MEDICAL OFFICER | 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080 |
Mcpartland Mark A. | officer: VP CORPORATE DEVELOPMENT | C/O VISTAGEN THERAPEUTICS, INC. 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080 |
Gin Jerry B | director | 343 ALLERTON AVE SOUTH SAN FRANCISCO CA 94080 |
Underdown Brian J. | director | C/O LUMIRA CAPITAL INVESTMENT MANAGEMENT 141 ADELAIDE ST. WEST, SUITE 770 TORONTO ONTARIO CANADA M5H 3L5 A6 00000 |
Cunningham Ann Michelle | director | 255 N CALDWELL CIRCLE DOWNINGTOWN PA 19335 |
Rice A. Franklin | officer: VP CORPORATE DEVELOPMENT | 384 OYSTER POINT BLVD. SUITE 8 SOUTH SAN FRANCISCO CA 94080 |
Bonfiglio Gregory A. | director | 384 OYSTER POINT BOULEVARD, NO. 8 SOUTH SAN FRANCISCO CA 94080 |
Platinum Long Term Growth Vii, Llc | 10 percent owner | 152 WEST 57TH STREET 4TH FLOOR NEW YORK NY 10019 |
Cato Holding Co | 10 percent owner | 4364 SOUTH ALSTON AVENUE DURHAM NC 27713 |
Cato Allen Easley | 10 percent owner | 4364 SOUTH ALSTON AVENUE DURHAM NC 27713 |
Jones Stephanie | director, 10 percent owner, officer: PRESIDENT | 13834 W. HOYT ROAD RATHDRUM ID 83858 |
From GuruFocus
Other Sources
By Fool 2021-06-30
By Zacks 2021-06-16
By tipranks.com 2022-02-13
By Zacks 2021-02-11
By Zacks 2021-11-10
By Zacks 2022-02-10
By Zacks 2021-08-12
By Zacks 2021-03-11
By tipranks.com 2022-03-03
By Seekingalpha 2021-11-10
By Seekingalpha 2022-02-10
By Seekingalpha 2021-01-24